NCT04117763View on ClinicalTrials.gov

Effect of Empagliflozin on Ventricular Repolarization.

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Diabetes Mellitus, Type 2Coronary Heart DiseaseArrythmia, Cardiac
Interventions
DRUG

Empagliflozin 25 MG

Empagliflozin once daily, for three months

Trial Locations (1)

05403-000

InCor, São Paulo

All Listed Sponsors
lead

University of Sao Paulo

OTHER

NCT04117763 - Effect of Empagliflozin on Ventricular Repolarization. | Biotech Hunter | Biotech Hunter